Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Return on Invested Capital (2017 - 2025)

Avalo Therapeutics (AVTX) has disclosed Return on Invested Capital for 9 consecutive years, with 0.68% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Invested Capital rose 1614.0% year-over-year to 0.68%, compared with a TTM value of 0.68% through Sep 2025, up 1614.0%, and an annual FY2024 reading of 0.98%, down 1613.0% over the prior year.
  • Return on Invested Capital was 0.68% for Q3 2025 at Avalo Therapeutics, down from 0.53% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 11.67% in Q3 2022 and bottomed at 343.29% in Q2 2022.
  • Average Return on Invested Capital over 5 years is 19.08%, with a median of 0.89% recorded in 2024.
  • The sharpest move saw Return on Invested Capital crashed -34048bps in 2022, then skyrocketed 34642bps in 2023.
  • Year by year, Return on Invested Capital stood at 2.59% in 2021, then surged by 324bps to 5.79% in 2022, then plummeted by -143bps to 2.49% in 2023, then surged by 64bps to 0.89% in 2024, then grew by 24bps to 0.68% in 2025.
  • Business Quant data shows Return on Invested Capital for AVTX at 0.68% in Q3 2025, 0.53% in Q2 2025, and 0.39% in Q1 2025.